Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer.

Published in: Cancer chemotherapy and pharmacology (2022)

The PBPK model predicted a significant drug interaction when ponatinib was combined with a strong CYP3A4 inducer. Conversely, the combination with weak-to-strong CYP3A4 inhibitors did not suggest a drug interaction with ponatinib.

Keyphrases

chronic myeloid leukemia
adverse drug
emergency department